HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use NIVESTYM safely and effectively. See full prescribing information for NIVESTYM.
NIVESTYM™ (filgrastim-aafi) injection, for subcutaneous or intravenous use
Initial U.S. Approval: 2018
NIVESTYM (filgrastim-aafi) is biosimilar1 to NEUPOGEN (filgrastim).
RECENT MAJOR CHANGES
INDICATIONS AND USAGE
NIVESTYM is a leukocyte growth factor indicated to
DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHS
Patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors such as filgrastim products or pegfilgrastim products. (4)
WARNINGS AND PRECAUTIONS
Most common adverse reactions in patients:
To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.